News

Find News

Filter articles

Applied Filters

Showing 1 to 10 of 1047 results

Swiss pharma company reveals SCOTUS appeal plans

US22-09-2022Staff Writer

Federal Circuit denies petition to rehear dispute over multiple sclerosis medicine | Company will petition highest court over invalidity ruling.

Big pharma firm settles HIV drug disputes with generic makers

US13-09-2022Staff Writer

Gilead had filed patent infringement proceedings lawsuit against five companies | Drug makers will receive non-exclusive licences starting from Halloween 2031.

Generic maker urges review of $235m skinny label decision

US08-09-2022Muireann Bolger

A split Federal Circuit revived a 2017 jury verdict that Teva had infringed GSK drug | Israeli pharma firm warns of threat to availability of low-cost generic medicines.

Novartis sued over blockbuster heart failure drug

US30-08-2022Muireann Bolger

Pharma company facing lawsuit from two universities | Dispute centres on therapeutically effective co-crystals patent.

Gilead must face pay-for-delay suit

US23-08-2022Staff Writer

Class-action alleges pharma company blocked rival HIV drug | Health insurance trust convinces judge a reverse payment may have been made.

Chugai settles cancer drug patent dispute with US firm

Japan, US10-08-2022Staff Writer

Parties to withdraw lawsuit over lung cancer drug | ANDA generic would have displaced sales of patented version in Delaware, said plaintiff.

Pharma unit could get green light to launch IBS generic

US02-08-2022Staff Writer

Dispute centres on Xifaxan, used to treat irritable bowel syndrome | ‘Significant hurdle’ cleared in bringing drug to market | Bausch wins partial victory after Alvogen subsidiary failed to show that patent claims were obvious.

ViiV Healthcare signs deal to boost HIV drug access

Africa, Switzerland29-07-2022Staff writer

Pharma firm joins with patent pool to expand access to HIV treatment | 90 countries set to benefit from preventative medicine

Competition watchdog fines big pharma duo £70m

UK22-07-2022Staff writer

The pair are rapped for overcharging the NHS | Unfair prices for an epilepsy drug lasted four years | Costs leapt from £2m to £50m in one year after the companies' “illegal exploitation” of market position.

Generic maker pays $145m to settle antitrust suit

US21-07-2022Staff writer

California company resolves pay-for-delay issue over opioids | Allegations were brought by direct purchasers eight years ago.

Showing 1 to 10 of 1047 results

LSIPR